In NB, the somatically acquired genomic amplification and activating mutations of ALK occur in 2–3% and 8–10% of primary tumors, respectively [48,52,53], and play an important role in NB oncogenesis [54], evidently associated with a poor outcome [4,5]. Here, ALK is linked to neuroblastoma.